should glp-1 agonists be open access Updated guidance for patients using GLP-1/GIP receptor A clinician's perspective 📝 GLP-1

GLP-1 agonists primarily cause gastrointestinal effectsnausea, vomiting, constipation, or diarrheathat typically subside within weeks as the body adjusts

These impacts included improved cardiovascular benefits, less joint pain, lower cholesterol and blood pressure, improved mood and energy levels and more

Second, many effective tools are available to manage obesity, but they are not widely used, for a variety of reasons

Acknowledgements: The authors would like to thank Sarah Minter and Benjamin Smith for comments on an early version of the manuscript

[DOI] [PMC free article] [PubMed] [Google Scholar] 42.Wadden T.A., Tronieri J.S., Sugimoto D., Lund M.T., Auerbach P., Jensen C., Rubino D

doi: 10.1185/03007995.2015.1117433